≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Labyrinthine dysfunction

DOID Endpoint Browser

H8_LABYRDYSFUNC

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — H83.2
  • Cause of death: ICD-10 — H83.2

2 out of 7 registries used, show all original rules.

28

4. Check minimum number of events

None

28

5. Include endpoints

None

28

6. Filter based on genotype QC (FinnGen only)

28

Control definitions (FinnGen only)

Control exclude
H8_INNER

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
H83
Name in latin
Dysfunctio labyrinthi

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 156 94 62
Only index persons 152 91 61
Unadjusted period prevalence (%)
Whole population 0.00 0.00 0.00
Only index persons 0.00 0.00 0.00
Median age at first event (years)
Whole population - 52.39 52.86
Only index persons 52.25 51.37 53.58

-FinnGen-

Key figures

All Female Male
Number of individuals 28 15 13
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 56.17 54.87 57.67

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

No data available

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
7
26
3.24
1.71
1.3
1.5
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
22
156
2.91
1.59
2.3
3.0
—
—
—
0
0
(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma
9
41
2.75
1.55
4.7
2.6
ng/l
286.3
15.0
—
9
28
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
8
35
2.79
1.41
1.4
1.9
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
6
24
2.90
1.39
1.3
1.4
—
—
—
0
0
(3013650) Neutrophils [#/volume] in Blood by Automated count
19
132
2.36
1.33
7.7
11.1
e9/l
4.1
4.1
0.03
14
116
(3033658) Prothrombin time (PT) actual/Normal
9
49
2.23
1.13
6.3
4.4
%
74.0
89.3
—
9
49
(3042936) Bacteria identified in Isolate by Culture
6
32
2.11
0.87
1.5
2.1
—
—
—
0
0
(3022096) Basophils/100 leukocytes in Blood
14
95
1.95
0.86
7.9
5.9
%
0.9
0.7
0.63
14
90
(36304419) Bacteria [Presence] in Urine
10
60
2.04
0.86
2.8
3.1
—
—
—
0
0
(3000492) Spirometry study
0
25
0.00
0.84
0.0
1.4
—
—
—
0
0
(3025839) Triglyceride [Moles/volume] in Serum or Plasma
8
48
1.93
0.71
1.8
1.7
mmol/l
0.8
1.2
—
8
42
(3002030) Lymphocytes/100 leukocytes in Blood
14
100
1.80
0.70
8.1
5.9
%
30.9
27.7
0.66
14
93
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
0
22
0.00
0.62
0.0
1.2
—
—
—
0
0
(42870588) Differential panel, method unspecified - Blood
10
69
1.70
0.53
7.6
5.2
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
11
79
1.65
0.51
2.6
3.2
—
—
—
0
0
(40758558) Short blood count panel - Blood
8
56
1.60
0.48
6.8
7.7
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
9
64
1.60
0.46
2.2
2.4
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
5
34
1.57
0.43
1.0
1.3
—
—
—
0
0
(3026989) Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
0
15
0.00
0.42
0.0
4.0
—
4.3
—
0
15
(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma
0
16
0.00
0.42
0.0
1.2
—
159.2
—
0
5
(3030981) Hyaline casts [#/volume] in Urine by Automated count
0
16
0.00
0.42
0.0
1.8
—
0.0
—
0
16
(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum
0
18
0.00
0.41
0.0
2.3
—
—
—
0
0
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
0
18
0.00
0.41
0.0
1.2
—
—
—
0
0
(36660697) Celiac disease serology panel - Serum
0
18
0.00
0.41
0.0
1.2
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
6
87
0.61
0.41
2.0
2.3
—
—
—
0
0
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
6
44
1.46
0.37
2.2
2.4
—
—
—
0
0
(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma
5
72
0.63
0.31
6.4
4.6
ug/l
1.1
2.0
—
5
64
(3009542) Hematocrit [Volume Fraction] of Blood
23
208
1.59
0.31
22.1
14.6
%
41.0
40.5
0.15
16
170
(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma
7
90
0.70
0.28
4.6
4.7
ng/l
285.3
27.3
—
7
65
(40768804) Tissue Pathology biopsy report
11
89
1.39
0.26
1.6
1.9
—
—
—
0
0
(40761511) CBC panel - Blood by Automated count
23
243
0.70
0.25
12.3
11.8
—
—
—
0
0
(4034850)
0
11
0.00
0.22
0.0
31.4
—
—
—
0
0
(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
0
11
0.00
0.22
0.0
1.3
—
—
—
0
0
(3022621) pH of Urine by Test strip
0
11
0.00
0.22
0.0
2.4
—
—
—
0
0
(3025941) Bacteria identified in Stool by Culture
0
11
0.00
0.22
0.0
1.0
—
—
—
0
0
(3017766) Complement C4 [Mass/volume] in Serum or Plasma
0
10
0.00
0.22
0.0
1.2
—
0.2
—
0
10
(3004716) Salmonella sp identified in Stool by Organism specific culture
0
10
0.00
0.22
0.0
1.3
—
—
—
0
0
(3000620) Complement C3 [Mass/volume] in Serum or Plasma
0
10
0.00
0.22
0.0
1.2
—
1.2
—
0
10
(3019832) Treponema pallidum Ab [Presence] in Serum
0
10
0.00
0.22
0.0
1.4
—
—
—
0
0
(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma
0
14
0.00
0.20
0.0
4.0
—
87.4
—
0
14
(3021879) Hepatitis B virus core Ab [Presence] in Serum
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
(3041096) Erythrocytes [Presence] in Urine by Automated
5
67
0.69
0.19
3.0
2.5
—
—
—
0
0
(3015377) Calcium [Moles/volume] in Serum or Plasma
6
76
0.73
0.18
1.7
3.7
mmol/l
2.4
2.3
—
6
69
(3044889) 12 lead EKG panel
15
167
0.78
0.17
4.3
3.8
—
—
—
0
0
(3037467) Urinalysis macro (dipstick) panel - Urine
17
153
1.28
0.17
3.4
3.8
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
6
56
1.09
0.09
1.2
1.4
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
7
62
1.17
0.09
2.3
2.5
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
8
91
0.83
0.08
3.1
3.4
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
11
100
1.16
0.06
2.8
3.4
—
—
—
0
0
(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
18
171
1.15
0.05
6.5
7.8
u/l
69.1
75.4
0.58
18
160
(3019473) Protein [Mass/volume] in Cerebral spinal fluid
0
9
0.00
0.00
0.0
1.2
—
476.6
—
0
9
(3020961) Endomysium IgA Ab [Titer] in Serum
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
(3023150) Myeloperoxidase Ab [Units/volume] in Serum
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
(3022313) Gas panel - Capillary blood
0
9
0.00
0.00
0.0
3.8
—
—
—
0
0
(3032836) C peptide [Moles/volume] in Serum or Plasma --fasting
0
5
0.00
0.00
0.0
1.0
—
1.2
—
0
5
(3000330) Specific gravity of Urine by Test strip
0
7
0.00
0.00
0.0
3.4
—
—
—
0
0
(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(3038515) Glucose [Moles/volume] in Venous blood
0
5
0.00
0.00
0.0
3.4
—
5.7
—
0
5
(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(3005895) Myoglobin [Mass/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
2.6
—
119.1
—
0
7
(3020044) Glucose [Moles/volume] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
1.3
—
3.9
—
0
6
(3023420) DNA double strand Ab [Units/volume] in Serum
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
(1761482) Bacteria [#/volume] in Urine by Culture
0
5
0.00
0.00
0.0
3.8
—
—
—
0
0
(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3001405) CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood
0
5
0.00
0.00
0.0
3.0
—
645.8
—
0
5
(3014702) Chromogranin A [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
2.8
—
2.3
—
0
5
(3023368) Bacteria identified in Blood by Culture
6
58
1.04
0.00
4.3
4.5
—
—
—
0
0
(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
0
5
0.00
0.00
0.0
10.0
—
54.4
—
0
5
(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3004490) Bicarbonate [Moles/volume] standard in Capillary blood
0
8
0.00
0.00
0.0
4.1
—
26.2
—
0
8
(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3015736) pH of Urine
9
88
1.03
0.00
2.1
3.7
—
—
—
0
0
(36305247) Microscopic observation [Identifier] in Isolate by Gram stain
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
(3009508) Creatinine [Moles/volume] in Urine
6
58
1.04
0.00
1.8
3.3
mmol/l
8.7
7.2
—
6
51
(3025271) CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood
0
5
0.00
0.00
0.0
2.8
—
0.1
—
0
5
(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(3011397) Hemoglobin [Presence] in Urine by Test strip
5
49
1.02
0.00
2.8
4.6
—
—
—
0
0
(3045414) Leukocytes [Presence] in Urine
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(44816559) Phosphatidylethanol [Mass/volume] in Blood
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
(3011288) Drugs identified in Urine by Screen method
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
(3008037) Lactate [Moles/volume] in Venous blood
0
5
0.00
0.00
0.0
3.4
—
1.4
—
0
5
(3044290) Cell count panel - Cerebral spinal fluid
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(3048929) Epstein Barr virus Ab [Presence] in Serum
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3050129) First trimester maternal screen panel - Serum or Plasma
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3019150) Specific gravity of Urine by Refractometry
5
52
0.95
0.00
2.4
4.5
—
1.0
—
0
6
(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay
0
7
0.00
0.00
0.0
2.1
—
—
—
0
0
(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint H8_LABYRDYSFUNC and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have H8_LABYRDYSFUNC.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: H8_LABYRDYSFUNC – Labyrinthine dysfunction

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data